[EN] METHODS FOR PRODUCING 3-HYDROXY-3-METHYLBUTYRIC ACID<br/>[FR] PROCÉDÉS POUR PRODUIRE DE L'ACIDE 3-HYDROXY-3-MÉTHYLBUTYRIQUE
申请人:GLOBAL BIOENERGIES
公开号:WO2016042012A1
公开(公告)日:2016-03-24
Described is a method for the conversion of 3-methylcrotonyl-CoA into 3-hydroxy-3- methylbutyric acid comprising the steps of: (a) enzymatically converting 3-methylcrotonyl-CoA into 3-hydroxy-3-methylbutyryl-CoA; and (b) further enzymatically converting the thus produced 3-hydroxy-3-methylbutyryl-CoA into 3-hydroxy-3-methylbutyric acid wherein the enzymatic conversion of 3-hydroxy-3-methylbutyryl-CoA into 3-hydroxy-3-methylbutyric acid according to step (b) is achieved by first converting 3-hydroxy-3-methylbutyryl-CoA into 3-hydroxy-3-methylbutyryl phosphate and then subsequently converting the thus produced 3-hydroxy-3-methylbutyryl phosphate into 3-hydroxy-3-methylbutyric acid.
[EN] MACROCYCLIC PANTETHEINE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS MACROCYCLIQUES DE LA PANTÉTHÉINE ET LEURS UTILISATIONS
申请人:COMET THERAPEUTICS INC
公开号:WO2021108579A1
公开(公告)日:2021-06-03
The present disclosure relates to compounds of Formulae (I) or (II): and pharmaceutically acceptable salts or solvates thereof. The present disclosure also relates to pharmaceutical compositions comprising the compounds and therapeutic and diagnostic uses of the compounds and pharmaceutical compositions.
[EN] COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES CHARACTERIZED BY INSUFFICIENT PANTOTHENATE KINASE ACTIVITY<br/>[FR] COMPOSITIONS ET MÉTHODES UTILES DANS LE TRAITEMENT DE MALADIES SE CARACTÉRISANT PAR UNE ACTIVITÉ INSUFFISANTE DE LA PANTOTHÉNATE KINASE
申请人:ACIES BIO D O O
公开号:WO2017218963A1
公开(公告)日:2017-12-21
Methods and pharmaceutical compositions for use in treating diseases associated with insufficient activity of the pantothenate kinase enzyme (e.g., CASTOR diseases) are disclosed. The methods and compositions involve an effective amount of an active derivative of 4'-phosphopantetheine.
biosynthesized from acyl-CoA precursors by polyketide synthases. One of the limitations to combinatorial biosynthesis of polyketides has been the lack of a toolkit that describes the means of delivering novel acyl-CoA precursors necessary for polyketide biosynthesis. Using five acid-CoA ligases obtained from various plants and microorganisms, we biosynthesized an initial library of 79 acyl-CoA thioesters by screening
The invention provides human enzymes (NZMS) and polynucleotides which identify and encode NZMS. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of NZMS.